Filing Flows › Health Care › Cocrystal Pharma (COCP)
Cocrystal Pharma (COCP) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Cocrystal Pharma (COCP) Q2 2026 earnings results →
Cocrystal Pharma made $105K in Q2 2026. Operating margin n/m, net loss $3.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $105K in Q2 2026, down 53% from the previous quarter.
Operating costs exceeded revenue by $3.2M, an operating margin of -3032.4%. The quarter ended with a net loss of $3.2M, wider than the previous quarter's $2.3M loss.
Operating cash flow was −$2.5M. Non-cash charges added back $12K of depreciation and amortization and $92K of share-based compensation. Working capital and other items added $544K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $105K | — | n/m | −$3.2M | −$2.5M |
| Q1 2026 | 10-Q | May 15, 2026 | $225K | — | n/m | −$2.3M | −$2.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cocrystal Pharma
Cocrystal Pharma, Inc. (the “Company” or “Cocrystal”) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise with the goal of creating viable antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by RNA viruses including influenza virus, norovirus, coronaviruses (including SARS-CoV-2 & MERS-CoV), respiratory virus infections and hepatitis C virus (“HCV”) infections.
In its own words, from its 10-K, filed Mar 31, 2026.
Cocrystal Pharma against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| COCP Cocrystal Pharma | Q2 2026 | $105K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Cocrystal Pharma 10-Q on SEC EDGAR · CIK 1412486 · Pharmaceutical Preparations
13F: who owns COCP and who is buying
More on COCP
History
Every quarter: Q2 2026 results · Q1 2026 results